Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial

Conclusions: Limited-duration celecoxib prevents adenoma recurrence in patients with prior high-risk adenomas, in whom strategies to minimize cardiovascular toxicity might be feasible.

Source: JNCI - August 15, 2016 Category: Cancer & Oncology Authors: Thompson, P. A., Ashbeck, E. L., Roe, D. J., Fales, L., Buckmeier, J., Wang, F., Bhattacharyya, A., Hsu, C.-H., Chow, S. H. H., Ahnen, D. J., Boland, C. R., Heigh, R. I., Fay, D. E., Hamilton, S. R., Jacobs, E. T., Martinez, E. M., Alberts, D. S., Lance, Tags: Article Source Type: research